Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2028

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing and Clinical Trials Insight 2028 Report Overview:

Controlled Release Drug Delivery Market Opportunity: > 90 Billion By 2028
Global and Regional Market Forecast Till 2028
Controlled Release Drug Clinical Pipeline Insight By Phase, Indication, Company, Country and Drug Class
Comprehensive Clinical insight On More Than 200 Drug in Clinical Trials
Comprehensive Clinical insight On More Than 150 Drug Available in market
Drug Pricing, Patent and Dosage Insight By indication: Alzheimer’s, Parkinson’s, Schizophrenia , Chronic Pain, Multiple Sclerosis, Diabetes Mellitus, Hypertension and Angina Pectoris

The search for innovative solution to the problems associated with the delivery of the drugs ended with the arrival of controlled release drug market in the pharmaceutical sector. In the past few years, the novel and mechanistic approach followed by the controlled release drugs in the treatment regimen has brought great appreciation in the pharmaceutical industry. To a greater extent, the market involves the maintenance of the drug concentration inside the patient within a range that is desired. Along with this the market also ensures significant advantages such as non-toxicity and biocompatibility of the materials used to administer drug inside the patient.

Controlled release drug mechanism has provided novel delivery platform that can be optimized, thus resulting in the generation of a robust, strong and impressive pipeline of the controlled release drugs for the broad-spectrum diseases like cancer, infectious diseases, autoimmune diseases, inflammatory diseases and neurological affections. Already available controlled release drugs categorized under tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) or glucagon-like peptide-1 (GLP-1) analogues for diabetes have been completely revolutionizing the pharmaceutical market by increasing the survival rate of the patients and who have been receiving major toxicity and side-effects due to unwanted concentration of the drug inside the body.

The efforts involved in the development of the market and associated parameters have helped the market to deliver promising results, thus, making the controlled release mechanism as one of the widely accepted and appreciated drug delivery system. Drug developers are now adopting to controlled release mechanism of delivering the drug in order to push the sales of the new as well existing drugs for key indications. Also, diminished side effects, reduced toxicity and maximum precision are some of the factors with which controlled release drugs are getting continuous level of acceptance from the researchers as well as the patients. It is estimated that the advent of control release technology as an important supportive technology in therapeutics sector is shaping the market towards success which researchers and patients were in need for a long period of time.

As per Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing and Clinical Trials Insight 2028 report findings, the arrival of the respective drug delivery market has brought a fundamental change and transformation shift in the pharmaceutical sector as it has slated every limits that were there in the previous markets which were leading to the development of unwanted side-effects in the patients. The market is also attracting several novel patients as the wide applications received by the older patients are expected to increase the bars of the markets with respect to advantages and benefits. Through the analysis of the market, it can be observed that development of safe as well as effective controlled release drugs by the researchers and the clinicians is estimated to provide the market specific pharmacotherapeutic regimens, leading to wide-adoption of the market. Furthermore, the robust clinical pipeline of the market and its impact on delivering the desired concentration of the drug is suggesting high-end future growth in every indication. It is believed that the market will soon explore the hidden applications as the research teams associated with the market across the globe is packed with enough data to drive the future prospects of the drug delivery system.

controlled drug deliver controlled drug delivery market controlled drug delivery companies controlled drug delivery market size controlled drug delivery market forecast controlled drug delivery drug sales controlled release drug delivery market controlled release drug delivery market size controlled release drug delivery market system controlled release drug delivery market report controlled release drug delivery market growth controlled release drug delivery market forecast controlled release drug delivery market future controlled release drug delivery market sales controlled release drug delivery market companies controlled release drug delivery market companies controlled release drug delivery market clinical trials controlled release drug delivery market drugs controlled release drug delivery market development

Introduction to Controlled Drug Delivery

1.1 Novel Drug Delivery Systems

1.2 Preamble to Controlled Drug Delivery

1.3 Drug Delivery Technology

1.4 Fundamentals of Controlled Delivery

1.5 Basis for Controlled Drug Delivery

1.6 Controlled Drug Delivery Mechanism of Action

Controlled Drug Delivery Classification

2.1 By Delivery Systems

2.2 By Technology

2.3 By Routes of Delivery

2.4 Material Based Approaches for Controlled Drug Delivery

Global Controlled Drug Market Overview and Recent Trends at Regional Level

3.1 US

3.2 Europe

3.3 Japan

Global Controlled Release Drug Clinical Pipeline Overview

4.1 By Phase

4.2 By Company

4.3 By Country/Region

4.4 By Drug Class

4.5 By Indication

Controlled Release Drugs for Alzheimer’s Disease - Pricing, Patent and Dosage Insight

5.1 Namzaric (Extended-Release)

5.2 Namenda XR (Extended – Release)

5.3 Razadyne ER (Extended – Release)

Controlled Release Drugs for Parkinson’s Disease - Pricing, Patent and Dosage Insight

6.1 Gocovri (Extended- Release)

6.2 Osmolex ER (Extended - Release)

Controlled Release Drugs for Schizophrenia - Pricing, Patent and Dosage Insight

7.1 Perseris (Extended – Release)

7.2 Invega (Extended – Release)

7.3 Invega Sustenna/Invega Trinza (Extended – Release)

7.4 Seroquel XR (Extended – Release)

7.5 Abilify Maintena (Extended – Release)

7.6 Aristada (Extended – Release)

Controlled Release Drugs for Chronic Pain - Pricing, Patent and Dosage Insight

8.1 Hysingla ER (Extended – Release)

8.2 Nucynta ER (Extended – Release)

8.3 Kadian (Extended – Release)

8.4 Xtampza ER (Extended – Release)

8.5 MS Contin (Extended – Release)

8.6 Embeda (Extended – Release)

Controlled Release Drugs for Multiple Sclerosis - Pricing, Patent and Dosage Insight

9.1 Ampyra (Extended – Release)

9.2 Tecfidera (Delayed – Release)

9.3 Rayos (Delayed – Release)

9.4 Vumerity (Delayed – Release)

Controlled Release Drugs for Diabetes Mellitus Type II - Pricing, Patent and Dosage Insight

10.1 Glumetza (Extended – Release)

10.2 Glucotrol XL (Extended – Release)

10.3 Fortamet (Extended – Release)

10.4 Glucophage XR (Extended – Release)

10.5 Bydureon (Extended – Release)

Controlled Release Drugs for Hypertension and Angina Pectoris - Pricing, Patent and Dosage Insight

11.1 Procardia XL (Extended – Release)

11.2 Toprol XL (Extended – Release)

11.3 Adalat CC (Extended – Release)

11.4 Verelan PM (Extended – Release)

11.5 Plendil (Extended – Release)

11.6 Cardizem LA (Extended – Release)

Global Controlled Drug Clinical Trials Insight By Company, Indication and Phase

12.1 Research

12.2 Preclinical

12.3 Clinical

12.4 Phase-I

12.5 Phase-I/II

12.6 Phase-II

12.7 Phase-II/III

12.8 Phase-III

12.9 Preregistration

12.10 Registered

Marketed Controlled Drug Clinical Insight By Company and Indication

Global Controlled Drug Delivery Market Dynamics

14.1 Market Drivers

14.2 Challenges to be Resolved

Global Controlled Drug Delivery Market Future Outlook

Competitive Landscape

16.1 AbbVie

16.2 Adare Pharma Solutions

16.3 Assertio Therapeutics

16.4 Astellas Pharma

16.5 AstraZeneca

16.6 Bristol-Myers Squibb

16.7 GlaxoSmithKline

16.8 Pfizer

16.9 Sanofi

16.10 Supernus Pharmaceuticals

16.11 Takeda

Figure 1-1: Limitations of the Conventional Drug Delivery Systems

Figure 1-2: Diversification of the Novel Drug Delivery Platforms

Figure 1-3: History of Drug Delivery Technology from First Generation till Third

Generation

Figure 1-4: Barriers to be Overcome by the Third Generation Drug Delivery System

Figure 1-5: Demonstration of the Targeted and Non-Targeted Drug Delivery

Figure 1-6: Controlled Drug Release is by Zero Order Mechanism

Figure 1-7: Differentiation of the Two Forms of the Diffusion Controlled

Mechanisms

Figure 1-8: Mechanism of Encapsulation Dissolution Controlled System

Figure 1-9: Osmotic Release of the Drug Delivery with the Controlled Mechanism

Figure 1-10: Illustration of Erosion Mechanisms Found in Matrix Systems

Figure 2-1: Plasma Concentration v/s Time Profile in Conventional and Controlled

Release

Figure 2-2: Comparison of Varied Modified Drug Release Systems

Figure 2-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap

Figure 2-4: Classification Based Over the Technicality Erudition

Figure 2-5: Structural Differentiation among Varied Classified Drug Delivery

Systems

Figure 2-6: Classification Based over the Route of Administration

Figure 2-7: Categorization of Polymeric Controlled Drug Delivery Devices

Figure 2-8: Varied Nanostructures Available for the Nanoparticulate Delivery

System

Figure 3-1: US –Controlled Release Market Size (US$ Billion), 2020 - 2028

Figure 3-2: US – Population Above and Below 65 Years of Age (%), 2021

Figure 3-3: US – Share in Global Controlled Release Drug Market (%), 2021

Figure 3-4: Europe –Controlled Release Drug Delivery Market Size (US$ Billion),

2020 - 2028

Figure 3-5: Europe – Share in Global Controlled Release Drug Market (%), 2021

Figure 3-6: European Union – Population Above and Below 65 Years (%), 2021

Figure 3-7: European Union – Estimated Cases of Dementia, 2030 and 2050

Figure 3-8: Japan – Population Above and Below 65 Years (%), 2021

Figure 3-9: Japan – Dementia Cases (Million), 2018 and 2025

Figure 4-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2022

till 2028

Figure 4-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number),

2022 till 2028

Figure 4-3: Global - Controlled Release Drug Clinical Pipeline by Company

(Number), 2022 till 2028

Figure 4-4: Global - Controlled Release Drug Clinical Pipeline by Country/Region

(Number), 2022 till 2028

Figure 4-5: Global - Controlled Release Drug Clinical Pipeline by Drug Class

(Number), 2022 till 2028

Figure 4-6: Global - Controlled Release Drug Clinical Pipeline by indication

(Number), 2022 till 2028

Figure 5-1: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-7

mg, 10 mg-14 mg, 10 mg-21 mg, 10 mg–28 mg (US$), October’2022

Figure 5-2: Namenda XR – Available Dosage Strengths (mg), October 2022

Figure 5-3: Namenda XR – Price of 30 Oral Capsules, Extended Release of Dosage 7

mg, 14 mg, 21 mg, 28 mg (US$), October 2022

Figure 5-4: Namenda XR – Price of 90 Oral Capsules, Release of Dosage 14 mg, 28

mg (US$), October 2022

Figure 5-5: Razadyne XR – Available Dosage Strengths (mg), October 2022

Figure 5-6: Razadyne ER – Price of Oral Capsule, Extended Release of Dosage 8 mg,

16 mg, 24 mg (US$), October’2022

Figure 6-1: Gocovri XR – Available Dosage Strengths (mg), October 2022

Figure 6-2: Gocovri – Price of Oral Capsule, Extended Release of Dosage 68.5 mg,

137 mg (US$), October’2022

Figure 6-3: Global - Gocovri Quarterly Sales (US$ Million), H1’2022

Figure 6-4: Osmolex ER – Available Dosage Strengths (mg), October 2022

Figure 6-5: Osmolex – Price of Oral Capsule, Extended Release of Dosage 129 mg

(US$), October’2022

Figure 6-6: Osmolex – Price of Oral Capsule, Extended Release of Dosage 129 mg-

193 mg (US$), October’2022

Figure 6-7: Osmolex – Price of Oral Capsule, Extended Release of Dosage 193 mg

(US$), October’2022

Figure 7-1: Perseris: Available Dosage Strengths (mg)

Figure 7-2: Perseris: Price of 1 Subcutaneous Powder for Injection, Extended

Release (US$) October’2022

Figure 7-3: Perseris: Global Annual Sales (US$ Millions), 2019-2022*

Figure 7-4: Perseris: Global Quarterly Sales (US$ Millions), 2022

Figure 7-5: Invega – Available Dosage Strengths (mg)

Figure 7-6: Invega – Price of Oral Tablets, Extended Release of Dosage 1.5 mg, 3

mg, 6mg (US$), October’2022

Figure 7-7: Invega – Price of Oral Tablets, Extended Release of Dosage 9 mg (US$),

October’2022

Figure 7-8: Invega Sustenna – Available Dosage Strengths (mg)

Figure 7-9: Invega Trinza – Available Dosage Strengths (mg)

Figure 7-10: Invega Sustenna – Price of Intramuscular Suspension, Extended

Release of Dosage 39 mg (US$), October’2022

Figure 7-11: Invega Sustenna – Price of Intramuscular Suspension, Extended

Release of Dosage 78 mg (US$), October’2022

Figure 7-12: Invega Sustenna – Price of Intramuscular Suspension, Extended

Release of Dosage 117 mg (US$), October’2022

Figure 7-13: Invega Sustenna – Price of Intramuscular Suspension, Extended

Release of Dosage 156 mg (US$), October’2022

Figure 7-14: Invega Sustenna – Price of Intramuscular Suspension, Extended

Release of Dosage 234 mg (US$), October’2022

Figure 7-15: Invega Trinza – Price of Intramuscular Suspension Extended Release

273 mg (US$), October’2022

Figure 7-16: Invega Trinza – Price of Intramuscular Suspension Extended Release

410 mg (US$), October’2022

Figure 7-17: Invega Trinza – Price of Intramuscular Suspension Extended Release

546 mg (US$), October’2022

Figure 7-18: Invega Trinza – Price of Intramuscular Suspension Extended Release

819 mg (US$), October’2022

Figure 7-19: US - Invega Sustenna/ Invega Trinza Annual Global Sales (US$ Million),

2018-2022*

Figure 7-20: US - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 – Q3 (US$

Million), 2022

Figure 7-21: Seroquel XR – Available Dosage Strengths (mg)

Figure 7-22: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 50

mg (US$), October’2022

Figure 7-23: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 150

mg (US$), October’2022

Figure 7-24: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 200

mg (US$), October’2022

Figure 7-25: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 300

mg (US$), October’2022

Figure 7-26: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 400

mg (US$), October’2022

Figure 7-27: Global - Seroquel XR Total Annual Sales (US$ Million), 2017 - 2021

Figure 7-28: Global - Seroquel XR Quarterly Sales Q1 – Q4 (US$ Million), 2021

Figure 7-29: Abilify Maintena – Available Dosage Strengths (mg)

Figure 7-30: Abilify Maintena – Price of Intramuscular Powder for Injection,

Extended Release for Dosage 300 mg and 400 mg (US$), October’2022

Figure 7-31: Abilify Maintena – Global Annual Sales (US$ Million), 2019-2021

Figure 7-32: Aristada – Available Dosage Strengths (mg)

Figure 7-33: Aristada – Price of Intramuscular Suspension, Extended Release of

Dosage 441 mg (US$), October’2022

Figure 7-34: Aristada – Price of Intramuscular Suspension, Extended Release of

Dosage 662 mg (US$), October’2022

Figure 7-35: Aristada – Price of Intramuscular Suspension, Extended Release of

Dosage 882 mg (US$), October’2022

Figure 7-36: Aristada – Price of Intramuscular Suspension, Extended Release of

Dosage 1064 mg (US$), October’2022

Figure 7-37: Aristada - Global Annual Sales (US$ Million), 2018-2022*

Figure 7-38: Aristada - Quarterly Global Sales (US$ Million), H1’2022

Figure 8-1: Hysingla ER – Available Dosage Strengths (mg)

Figure 8-2: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 20 mg

(US$), October’2022

Figure 8-3: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 30 mg

(US$), October’2022

Figure 8-4: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 40 mg (US$), October’2022

Figure 8-5: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 60 mg (US$), October’2022

Figure 8-6: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 80 mg (US$), October’2022

Figure 8-7: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 100 mg (US$), October’2022

Figure 8-8: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 120 mg (US$), October’2022

Figure 8-9: Nucynta ER – Available Dosage Strengths (mg)

Figure 8-10: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 50 mg (US$), October’2022

Figure 8-11: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 100 mg (US$), October’2022

Figure 8-12: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 150 mg (US$), October’2022

Figure 8-13: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 200 mg (US$), October’2022

Figure 8-14: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 250 mg (US$), October’2022

Figure 8-15: Nucynta ER - Global Annual Sales (US$ Million), 2018-2022*

Figure 8-16: Nucynta ER - Global Quarterly Sales (US$ Million), H1’2022

Figure 8-17: Kadian – Available Dosage Strengths (mg)

Figure 8-18: Kadian – Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr (US$), October’2022

Figure 8-19: Kadian – Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr (US$), October’2022

Figure 8-20: Kadian – Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US$), October’2022

Figure 8-21: Kadian – Price of Oral Capsules, Extended Release of Dosage 80 mg/12 to 24 hr (US$), October’2022

Figure 8-22: Kadian – Price of Oral Capsules, Extended Release of Dosage 100 mg/12 to 24 hr (US$), October’2022

Figure 8-23: Kadian – Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr (US$), October’2022

Figure 8-24: Xtampza ER – Available Dosage Strengths (mg)

Figure 8-25: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 9 mg (US$), October’2022

Figure 8-26: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 13.5 mg (US$), October’2022

Figure 8-27: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 18 mg (US$), October’2022

Figure 8-28: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 27 mg (US$), October’2022

Figure 8-29: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 36 mg (US$), October’2022

Figure 8-30: Xtampza ER – Annual Global Sales (US$ Million), 2018-2022*

Figure 8-31: Xtampza ER - Quarterly Global Sales (US$ Million), H1’2022

Figure 8-32: MS Contin – Available Dosage Strengths (mg)

Figure 8-33: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US$), October’2022

Figure 8-34: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 30 mg/ 8 to 12 hr (US$), October’2022

Figure 8-35: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 60 mg/ 8 to 12 hr (US$), October’2022

Figure 8-36: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 100 mg/ 8 to 12 hr (US$), October’2022

Figure 8-37: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 200 mg/ 8 to 12 hr (US$), October’2022

Figure 8-38: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 20 mg-0.8 mg (US$), October’2022

Figure 8-39: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 30 mg-1.2mg (US$), October’2022

Figure 8-40: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 50 mg-2mg (US$), October’2022

Figure 8-41: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 60 mg-2.4 mg (US$), October’2022

Figure 8-42: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 80 mg-3.2mg (US$), October’2022

Figure 8-43: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 100 mg-4 mg (US$), October’2022

Figure 9-1: Ampyra – Price of Oral Tablet, Extended Release of Dosage 10 mg (US$), October’2022

Figure 9-2: Ampyra - Global Annual Sales (US$ Million), 2018-2022*

Figure 9-3: Ampyra - Global Quarterly Sales (US$ Million), H1’2022

Figure 9-4: Tecfidera – Available Dosage Strengths (mg)

Figure 9-5: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US$), October’2022

Figure 9-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 240 mg (US$), October’2022

Figure 9-7: Tecdifera Global Annual Sales (US$ Million), 2018-2022*

Figure 9-8: Global – Tecdifera Quarterly Sales (US$ Million), H1’2022

Figure 9-9: Rayos – Available Dosage Strengths (mg)

Figure 9-10: Rayos - Price of Oral Tablet, Delayed Release of All Dosages (US$), October’2022

Figure 9-11: Rayos - Global Annual Sales (US$ Million), 2018-2022*

Figure 9-12: Rayos - Global Quarterly Sales (US$ Million), H1’2022

Figure 9-13: Vumerity – Price of 231 mg Bottle, Delayed Release (US$), October’2022

Figure 9-14: Vumerity - Global Annual Sales (US$ Million), 2019-2022*

Figure 9-15: Vumerity - Global Quarterly Sales (US$ Million), H1’2022

Figure 10-1: Glumetza – Available Dosage Strengths (mg)

Figure 10-2: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 500 mg (US$), October’2022

Figure 10-3: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US$), October’2022

Figure 10-4: Glucotrol XL – Available Dosage Strengths (mg)

Figure 10-5: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 2.5 mg (US$), October’2022

Figure 10-6: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), October’2022

Figure 10-7: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), October’2022

Figure 10-8: Fortamet – Available Dosage Strengths (mg)

Figure 10-9: Global – Price of Fortamet Oral Tablets, Extended Release (US$), October’2022

Figure 10-10: Glucophage XR – Available Dosage Strengths (mg)

Figure 10-11: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 500 mg (US$), October’2022

Figure 10-12: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 750 mg (US$), October’2022

Figure 10-13: Global – Price of Bydureon Powder for Injection of Dosage 2 mg (US$), October’2022

Figure 10-14: Bydureon – Global Annual Sales (US$ Million), 2018-2022

Figure 10-15: Bydureon - Global Quarterly Sales (US$ Million), H1’2022

Figure 11-1: Procardia XL – Available Dosage Strengths (mg)

Figure 11-2: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), October’2022

Figure 11-3: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), October’2022

Figure 11-4: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 90 mg (US$), October’2022

Figure 11-5: Toprol XL – Available Dosage Strengths

Figure 11-6: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), October’2022

Figure 11-7: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), October’2022

Figure 11-8: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), October’2022

Figure 11-9: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), October’2022

Figure 11-10: Adalat CC – Available Dosage Strengths (mg)

Figure 11-11: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), October’2022

Figure 11-12: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), October’2022

Figure 11-13: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 90 mg (US$), October’2022

Figure 11-14: Verelan PM – Available Dosage Strengths (mg)

Figure 11-15: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US$), October’2022

Figure 11-16: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US$), October’2022

Figure 11-17: Plendil – Available Dosage Strengths (mg)

Figure 11-18: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 2.5 mg (US$), October’2022

Figure 11-19: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 5 mg (US$), October’2022

Figure 11-20: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 10 mg (US$), October’2022

Figure 11-21: Cardizem LA – Available Dosage Strengths (mg)

Figure 11-22: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), October’2022

Figure 11-23: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), October’2022

Figure 11-24: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), October’2022

Figure 11-25: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), October’2022

Figure 11-26: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), October’2022

Figure 11-27: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), October’2022

Figure 14-1: Accelerative Parameters of Controlled Drug Delivery Systems

Figure 14-2: Major Challenges Faced by Controlled Drug Delivery System

Figure 15-1: Global – Controlled Release Drug Delivery Market Size (US$ Billion), 2020 – 2028

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2028

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected